300601 康泰生物
已收盘 08-13 15:00:00
资讯
新帖
简况
8月7日康泰生物涨5.07%，疫苗ETF嘉实基金重仓该股
证券之星 · 08-07
8月7日康泰生物涨5.07%，疫苗ETF嘉实基金重仓该股
股市必读：康泰生物新发布《第八届董事会第十一次会议决议公告》
证券之星 · 08-07
股市必读：康泰生物新发布《第八届董事会第十一次会议决议公告》
康泰生物：全球首创双载体13价肺炎球菌多糖结合疫苗通过拉美、北非国家药监GMP检查
证券之星 · 08-06
康泰生物：全球首创双载体13价肺炎球菌多糖结合疫苗通过拉美、北非国家药监GMP检查
康泰生物（300601）披露关于向下修正‘康泰转2’转股价格的议案，8月5日股价上涨0.16%
证券之星 · 08-05
康泰生物（300601）披露关于向下修正‘康泰转2’转股价格的议案，8月5日股价上涨0.16%
康泰生物：8月4日董事刘建凯减持股份合计1.5万股
证券之星 · 08-05
康泰生物：8月4日董事刘建凯减持股份合计1.5万股
康泰生物：公司专门设立了mRNA及新型佐剂的研发团队
证券之星 · 08-05
康泰生物：公司专门设立了mRNA及新型佐剂的研发团队
康泰生物：公司积极推动五联苗Ⅲ期临床试验进程
证券之星 · 08-05
康泰生物：公司积极推动五联苗Ⅲ期临床试验进程
康泰生物：7月31日董事刘建凯减持股份合计8000股
证券之星 · 08-03
康泰生物：7月31日董事刘建凯减持股份合计8000股
康泰生物：7月30日董事刘建凯减持股份合计5000股
证券之星 · 07-31
康泰生物：7月30日董事刘建凯减持股份合计5000股
康泰生物（300601）披露关于康泰转2可能触发转股价格修正条件的提示性公告，7月29日股价上涨1.82%
证券之星 · 07-29
康泰生物（300601）披露关于康泰转2可能触发转股价格修正条件的提示性公告，7月29日股价上涨1.82%
康泰生物：与邹全明教授团队于2025年8月开展肺炎克雷伯菌超级细菌疫苗相关合作
证券之星 · 07-29
康泰生物：与邹全明教授团队于2025年8月开展肺炎克雷伯菌超级细菌疫苗相关合作
康泰生物：公司积极推动五联苗Ⅲ期临床试验进程
证券之星 · 07-29
康泰生物：公司积极推动五联苗Ⅲ期临床试验进程
康泰生物：预防慢性乙肝临床治愈人群HBsAg复阳的重组乙型肝炎疫苗
证券之星 · 07-29
康泰生物：预防慢性乙肝临床治愈人群HBsAg复阳的重组乙型肝炎疫苗
康泰生物：mRNA技术路径主要聚焦于RSV、带状疱疹疫苗等产品的开发
证券之星 · 07-29
康泰生物：mRNA技术路径主要聚焦于RSV、带状疱疹疫苗等产品的开发
7月17日康泰生物跌5.53%，疫苗ETF嘉实基金重仓该股
证券之星 · 07-17
7月17日康泰生物跌5.53%，疫苗ETF嘉实基金重仓该股
康泰生物：7月15日董事刘建凯减持股份合计4.1万股
证券之星 · 07-16
康泰生物：7月15日董事刘建凯减持股份合计4.1万股
康泰生物：7月14日董事刘建凯减持股份合计2.9万股
证券之星 · 07-15
康泰生物：7月14日董事刘建凯减持股份合计2.9万股
股市必读：康泰生物（300601）7月8日董秘有最新回复
证券之星 · 07-09
股市必读：康泰生物（300601）7月8日董秘有最新回复
康泰生物（300601）披露可转换公司债券2026年付息公告，7月8日股价下跌0.96%
证券之星 · 07-08
康泰生物（300601）披露可转换公司债券2026年付息公告，7月8日股价下跌0.96%
康泰生物：公司积极推动五联苗Ⅲ期临床试验进程
证券之星 · 07-08
康泰生物：公司积极推动五联苗Ⅲ期临床试验进程
暂无数据
公司概况
公司名称：
深圳康泰生物制品股份有限公司
所属行业：
医药制造业
上市日期：
2017-02-07
主营业务：
深圳康泰生物制品股份有限公司的主营业务是人用疫苗的研发、生产和销售。公司的主要产品是免疫规划疫苗、非免疫规划疫苗。
发行价格：
3.29
{"stockData":{"symbol":"300601","market":"SZ","secType":"STK","nameCN":"康泰生物","latestPrice":12.78,"timestamp":1786604637000,"preClose":12.66,"halted":0,"volume":21920093,"delay":0,"changeRate":0.0095,"floatShares":900000000,"shares":1117000000,"eps":0.0728,"marketStatus":"已收盘","change":0.12,"latestTime":"08-13 15:00:00","open":12.64,"high":13.02,"low":12.43,"amount":281000000,"amplitude":0.0466,"askPrice":12.79,"askSize":134,"bidPrice":12.78,"bidSize":1766,"shortable":0,"etf":0,"ttmEps":0.0728,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1786671000000},"marketStatusCode":5,"adr":0,"adjPreClose":12.66,"symbolType":"stock","openAndCloseTimeList":[[1786584600000,1786591800000],[1786597200000,1786604400000]],"highLimit":13.93,"lowLimit":11.39,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":1116930267,"isCdr":false,"pbRate":1.54,"roa":"--","peRate":175.549451,"roe":"0.35%","epsLYR":0.06,"committee":0.359571,"marketValue":14274000000,"turnoverRate":0.0243,"status":0,"floatMarketCap":11507000000},"requestUrl":"/m/hq/s/300601/tweets","defaultTab":"tweets","newsList":[{"id":"2657616948","title":"8月7日康泰生物涨5.07%，疫苗ETF嘉实基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2657616948","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657616948?lang=zh_cn&edition=full","pubTime":"2026-08-07 16:49","pubTimestamp":1786092547,"startTime":"0","endTime":"0","summary":"证券之星消息，8月7日康泰生物涨5.07%，收盘报12.85元，换手率2.97%，成交量26.78万手，成交额3.36亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共2家，其中持有数量最多的公募基金为嘉实基金的疫苗ETF嘉实。疫苗ETF嘉实目前规模为2.13亿元，最新净值0.6266，较上一交易日下跌1.12%，近一年上涨13.79%。疫苗ETF嘉实的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700028208.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["562860","BK0201","BK0239","300601","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657878654","title":"股市必读：康泰生物新发布《第八届董事会第十一次会议决议公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2657878654","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657878654?lang=zh_cn&edition=full","pubTime":"2026-08-07 02:35","pubTimestamp":1786041312,"startTime":"0","endTime":"0","summary":"公司公告汇总第八届董事会第十一次会议决议公告深圳康泰生物制品股份有限公司第八届董事会第十一次会议审议通过《关于董事会提议向下修正“康泰转2”转股价格及承诺未来期间不再提议向下修正转股价格的议案》。董事会提议下修转股价格，并提交股东大会审议；修正后价格不低于股东大会召开日前二十个交易日及前一交易日公司股票交易均价的较高者。议案尚需股东大会审议，持有本次可转债的股东应回避表决。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700002220.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300601","BK0046","BK0201"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657631030","title":"康泰生物：全球首创双载体13价肺炎球菌多糖结合疫苗通过拉美、北非国家药监GMP检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2657631030","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657631030?lang=zh_cn&edition=full","pubTime":"2026-08-06 20:52","pubTimestamp":1786020731,"startTime":"0","endTime":"0","summary":"2026年2月，公司全球首创双载体13价肺炎球菌多糖结合疫苗顺利通过拉美、北非国家药监GMP检查，充分验证了公司产品的生产设施、工艺流程、质量管控体系均符合该区域严格的药品生产质量管理规范，标志着产品已具备对应区域市场准入资质，为后续海外市场拓展、深化全球化战略落地奠定了坚实基础。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080600037602.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","159646","BK0046","BK0201","300601"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657523389","title":"康泰生物（300601）披露关于向下修正‘康泰转2’转股价格的议案，8月5日股价上涨0.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657523389","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657523389?lang=zh_cn&edition=full","pubTime":"2026-08-05 22:20","pubTimestamp":1785939630,"startTime":"0","endTime":"0","summary":"截至2026年8月5日收盘，康泰生物报收于12.48元，较前一交易日上涨0.16%，最新总市值为139.39亿元。该股当日开盘12.42元，最高12.58元，最低12.37元，成交额达1.32亿元，换手率为1.17%。近日，深圳康泰生物制品股份有限公司发布《关于召开2026年第一次临时股东会的通知》，宣布将于2026年8月21日召开2026年第一次临时股东会。会议将审议《关于董事会提议向下修正“康泰转2”转股价格及承诺未来期间不再提议向下修正转股价格的议案》。股权登记日为2026年8月18日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500043439.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300601","BK0201","BK0046","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657612547","title":"康泰生物：8月4日董事刘建凯减持股份合计1.5万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2657612547","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657612547?lang=zh_cn&edition=full","pubTime":"2026-08-05 21:01","pubTimestamp":1785934883,"startTime":"0","endTime":"0","summary":"证券之星消息，根据8月5日市场公开信息、上市公司公告及交易所披露数据整理，康泰生物最新董监高及相关人员股份变动情况：2026年8月4日公司董事,高管刘建凯共减持公司股份1.5万股，占公司总股本为0.0013%。康泰生物近半年内的董监高及核心技术人员增减持详情如下：康泰生物的高管列表及最新持股情况如下：融资融券数据显示该股近5日融资净流出765.02万，融资余额减少；融券净流入5.72万，融券余额增加。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500041681.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0201","BK0239","300601"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657764548","title":"康泰生物：公司专门设立了mRNA及新型佐剂的研发团队","url":"https://stock-news.laohu8.com/highlight/detail?id=2657764548","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657764548?lang=zh_cn&edition=full","pubTime":"2026-08-05 18:22","pubTimestamp":1785925348,"startTime":"0","endTime":"0","summary":"公司十分重视疫苗新技术路径的应用研究和新技术平台的建立，包括mRNA技术、病毒载体技术、新佐剂技术等。公司专门设立了mRNA及新型佐剂的研发团队，目前mRNA技术路径主要聚焦于RSV、带状疱疹疫苗等产品的开发，佐剂方面主要服务于公司在研管线中重组技术路径的在研产品，除了自主建设技术平台外，公司也持续加强对外合作，积极探索行业未来发展的方向。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500034212.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0201","300601","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657548991","title":"康泰生物：公司积极推动五联苗Ⅲ期临床试验进程","url":"https://stock-news.laohu8.com/highlight/detail?id=2657548991","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657548991?lang=zh_cn&edition=full","pubTime":"2026-08-05 18:18","pubTimestamp":1785925086,"startTime":"0","endTime":"0","summary":"证券之星消息，康泰生物(300601)08月05日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贵司5联苗什么时候出临床结果，康泰生物回复：您好，公司积极推动五联苗Ⅲ期临床试验进程，目前已完成受试者入组，后续如产品研发及注册进展达到信息披露标准，公司将会根据相关法律法规的规定履行信息披露义务。感谢您对公司的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500034031.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300601","BK0201","BK0046","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656371716","title":"康泰生物：7月31日董事刘建凯减持股份合计8000股","url":"https://stock-news.laohu8.com/highlight/detail?id=2656371716","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656371716?lang=zh_cn&edition=full","pubTime":"2026-08-03 21:01","pubTimestamp":1785762085,"startTime":"0","endTime":"0","summary":"证券之星消息，根据8月3日市场公开信息、上市公司公告及交易所披露数据整理，康泰生物最新董监高及相关人员股份变动情况：2026年7月31日公司董事,高管刘建凯共减持公司股份8000.0股，占公司总股本为0.0007%。康泰生物近半年内的董监高及核心技术人员增减持详情如下：康泰生物的高管列表及最新持股情况如下：融资融券数据显示该股近5日融资净流出861.35万，融资余额减少；融券净流入5.24万，融券余额增加。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080300034673.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","300601","BK0201"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655087369","title":"康泰生物：7月30日董事刘建凯减持股份合计5000股","url":"https://stock-news.laohu8.com/highlight/detail?id=2655087369","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655087369?lang=zh_cn&edition=full","pubTime":"2026-07-31 21:01","pubTimestamp":1785502884,"startTime":"0","endTime":"0","summary":"证券之星消息，根据7月31日市场公开信息、上市公司公告及交易所披露数据整理，康泰生物最新董监高及相关人员股份变动情况：2026年7月30日公司董事,高管刘建凯共减持公司股份5000.0股，占公司总股本为0.0004%。康泰生物近半年内的董监高及核心技术人员增减持详情如下：康泰生物的高管列表及最新持股情况如下：融资融券数据显示该股近5日融资净流出907.8万，融资余额减少；融券净流入6500.0，融券余额增加。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073100039679.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","300601","BK0201"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655899925","title":"康泰生物（300601）披露关于康泰转2可能触发转股价格修正条件的提示性公告，7月29日股价上涨1.82%","url":"https://stock-news.laohu8.com/highlight/detail?id=2655899925","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655899925?lang=zh_cn&edition=full","pubTime":"2026-07-29 22:27","pubTimestamp":1785335237,"startTime":"0","endTime":"0","summary":"截至2026年7月29日收盘，康泰生物报收于12.28元，较前一交易日上涨1.82%，最新总市值为137.16亿元。该股当日开盘12.07元，最高12.29元，最低11.98元，成交额达1.61亿元，换手率为1.47%。深圳康泰生物制品股份有限公司于2026年7月29日发布关于“康泰转2”可能触发转股价格修正条件的提示性公告。若触发条件，公司将于当日召开董事会审议是否修正转股价格，并及时履行信息披露义务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072900040592.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0201","BK0239","BK0046","300601"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655866948","title":"康泰生物：与邹全明教授团队于2025年8月开展肺炎克雷伯菌超级细菌疫苗相关合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2655866948","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655866948?lang=zh_cn&edition=full","pubTime":"2026-07-29 18:06","pubTimestamp":1785319570,"startTime":"0","endTime":"0","summary":"证券之星消息，康泰生物07月29日在投资者关系平台上答复投资者关心的问题。康泰生物回复：您好，公司与邹全明教授团队于2025 年 8 月开展了肺炎克雷伯菌超级细菌疫苗的相关合作。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072900030192.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159646","BK0201","BK0239","300601","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655866914","title":"康泰生物：公司积极推动五联苗Ⅲ期临床试验进程","url":"https://stock-news.laohu8.com/highlight/detail?id=2655866914","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655866914?lang=zh_cn&edition=full","pubTime":"2026-07-29 18:03","pubTimestamp":1785319390,"startTime":"0","endTime":"0","summary":"证券之星消息，康泰生物(300601)07月29日在投资者关系平台上答复投资者关心的问题。投资者提问：之前国家发文加速推动多联苗的发展，贵公司五联苗大概什么时候会进行三期揭盲？康泰生物回复：您好，公司积极推动五联苗Ⅲ期临床试验进程，目前已完成受试者入组，后续如产品研发及注册进展达到信息披露标准，公司将会根据相关法律法规的规定履行信息披露义务。感谢您对公司的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072900030053.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","300601","BK0201"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655866939","title":"康泰生物：预防慢性乙肝临床治愈人群HBsAg复阳的重组乙型肝炎疫苗","url":"https://stock-news.laohu8.com/highlight/detail?id=2655866939","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655866939?lang=zh_cn&edition=full","pubTime":"2026-07-29 18:03","pubTimestamp":1785319388,"startTime":"0","endTime":"0","summary":"证券之星消息，康泰生物07月29日在投资者关系平台上答复投资者关心的问题。康泰生物回复：您好，公司预防慢性乙肝临床治愈人群 HBsAg 复阳的重组乙型肝炎疫苗已获得药物临床试验批准通知书，该产品用于 16-64 岁慢性乙肝临床治愈人群预防乙型肝炎，以提高该人群乙肝表面抗体阳转率和抗体水平，预防该人群乙肝表面抗原清除后复阳的发生。当前乙肝治疗存在仍未满足的临床需求，缺乏可长期巩固疗效、降低复阳风险的策略。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072900030047.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","159646","BK0046","BK0201","300601"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655581866","title":"康泰生物：mRNA技术路径主要聚焦于RSV、带状疱疹疫苗等产品的开发","url":"https://stock-news.laohu8.com/highlight/detail?id=2655581866","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655581866?lang=zh_cn&edition=full","pubTime":"2026-07-29 18:00","pubTimestamp":1785319223,"startTime":"0","endTime":"0","summary":"公司十分重视疫苗新技术路径的应用研究和新技术平台的建立，包括mRNA技术、病毒载体技术、新佐剂技术等。公司专门设立了mRNA及新型佐剂的研发团队，目前mRNA技术路径主要聚焦于RSV、带状疱疹疫苗等产品的开发，佐剂方面主要服务于公司在研管线中重组技术路径的在研产品，除了自主建设技术平台外，公司也持续加强对外合作，积极探索行业未来发展的方向。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072900029974.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0201","300601","159646","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652060334","title":"7月17日康泰生物跌5.53%，疫苗ETF嘉实基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2652060334","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652060334?lang=zh_cn&edition=full","pubTime":"2026-07-17 16:54","pubTimestamp":1784278461,"startTime":"0","endTime":"0","summary":"证券之星消息，7月17日康泰生物跌5.53%，收盘报12.14元，换手率2.9%，成交量26.14万手，成交额3.24亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共2家，其中持有数量最多的公募基金为嘉实基金的疫苗ETF嘉实。疫苗ETF嘉实目前规模为2.25亿元，最新净值0.6651，较上一交易日下跌0.24%，近一年上涨13.79%。疫苗ETF嘉实的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071700030680.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300601","BK0201","562860","BK0046","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651421674","title":"康泰生物：7月15日董事刘建凯减持股份合计4.1万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2651421674","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651421674?lang=zh_cn&edition=full","pubTime":"2026-07-16 21:01","pubTimestamp":1784206911,"startTime":"0","endTime":"0","summary":"证券之星消息，根据7月16日市场公开信息、上市公司公告及交易所披露数据整理，康泰生物最新董监高及相关人员股份变动情况：2026年7月15日公司董事,高管刘建凯共减持公司股份4.1万股，占公司总股本为0.0037%。康泰生物近半年内的董监高及核心技术人员增减持详情如下：康泰生物的高管列表及最新持股情况如下：融资融券数据显示该股近5日融资净流出147.31万，融资余额减少；融券净流出1900.0，融券余额减少。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071600038512.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300601","BK0046","BK0201","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651654794","title":"康泰生物：7月14日董事刘建凯减持股份合计2.9万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2651654794","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651654794?lang=zh_cn&edition=full","pubTime":"2026-07-15 21:01","pubTimestamp":1784120501,"startTime":"0","endTime":"0","summary":"证券之星消息，根据7月15日市场公开信息、上市公司公告及交易所披露数据整理，康泰生物最新董监高及相关人员股份变动情况：2026年7月14日公司董事,高管刘建凯共减持公司股份2.9万股，占公司总股本为0.0026%。康泰生物近半年内的董监高及核心技术人员增减持详情如下：康泰生物的高管列表及最新持股情况如下：融资融券数据显示该股近5日融资净流出662.62万，融资余额减少；融券净流出3.63万，融券余额减少。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071500043222.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","BK0201","300601"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650723918","title":"股市必读：康泰生物（300601）7月8日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2650723918","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650723918?lang=zh_cn&edition=full","pubTime":"2026-07-09 02:22","pubTimestamp":1783534932,"startTime":"0","endTime":"0","summary":"截至2026年7月8日收盘，康泰生物报收于11.34元，下跌0.96%，换手率1.4%，成交量12.58万手，成交额1.43亿元。公司公告汇总：康泰生物发布“康泰转2”可转换公司债券2026年付息公告，第五年票面利率1.80%，每10张派息18.00元（含税），债权登记日为2026年7月14日，付息日为2026年7月15日。付息对象为中国结算深圳分公司登记在册的全体“康泰转2”持有人。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070900001793.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0201","300601","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649994252","title":"康泰生物（300601）披露可转换公司债券2026年付息公告，7月8日股价下跌0.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2649994252","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649994252?lang=zh_cn&edition=full","pubTime":"2026-07-08 22:36","pubTimestamp":1783521381,"startTime":"0","endTime":"0","summary":"截至2026年7月8日收盘，康泰生物报收于11.34元，较前一交易日下跌0.96%，最新总市值为126.66亿元。近日，深圳康泰生物制品股份有限公司发布关于“康泰转2”可转换公司债券2026年付息公告。本次付息为第五年付息，计息期间为2025年7月15日至2026年7月14日，票面利率为1.80%。债权登记日为2026年7月14日，付息日为2026年7月15日。付息对象为中国结算深圳分公司登记在册的全体“康泰转2”持有人。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070800043025.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300601","BK0046","BK0201"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649096967","title":"康泰生物：公司积极推动五联苗Ⅲ期临床试验进程","url":"https://stock-news.laohu8.com/highlight/detail?id=2649096967","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649096967?lang=zh_cn&edition=full","pubTime":"2026-07-08 18:21","pubTimestamp":1783506081,"startTime":"0","endTime":"0","summary":"证券之星消息，康泰生物(300601)07月08日在投资者关系平台上答复投资者关心的问题。投资者提问：贵公司5联苗3期进展如何？康泰生物回复：您好，公司积极推动五联苗Ⅲ期临床试验进程，目前已完成受试者入组，后续如产品研发及注册进展达到信息披露标准的，公司将会根据相关法律法规的规定履行信息披露义务。感谢您对公司的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070800035550.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0201","300601","BK0046","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1786633839964,"stockEarnings":[{"period":"1week","weight":0.0144},{"period":"1month","weight":0.0657},{"period":"3month","weight":-0.1255},{"period":"6month","weight":-0.1449},{"period":"1year","weight":-0.2723},{"period":"ytd","weight":-0.1403}],"compareEarnings":[{"period":"1week","weight":0.0176},{"period":"1month","weight":0.0084},{"period":"3month","weight":-0.0553},{"period":"6month","weight":-0.0332},{"period":"1year","weight":0.0766},{"period":"ytd","weight":-0.0056}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"深圳康泰生物制品股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"61919人(较上一季度增加1.07%)","perCapita":"14541股","listingDate":"2017-02-07","address":"广东省深圳市南山区粤海街道科技园社区科发路222号康泰集团大厦","registeredCapital":"111693万元","survey":" 深圳康泰生物制品股份有限公司的主营业务是人用疫苗的研发、生产和销售。公司的主要产品是免疫规划疫苗、非免疫规划疫苗。","listedPrice":3.29},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康泰生物(300601)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康泰生物(300601)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康泰生物,300601,康泰生物股票,康泰生物股票老虎,康泰生物股票老虎国际,康泰生物行情,康泰生物股票行情,康泰生物股价,康泰生物股市,康泰生物股票价格,康泰生物股票交易,康泰生物股票购买,康泰生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康泰生物(300601)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康泰生物(300601)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}